RXO’s valuation is a paradox wrapped in a conundrum. Despite a DCF value that suggests significant undervaluation, the market has priced it with a Forward P/E of 36.79, indicating high growth expectations. Yet, the negative Earnings Yield and a precarious Altman Z-score of 2.80 raise red flags about its financial stability. The company’s current valuation seems to ignore its operational inefficiencies, as evidenced by a negative ROIC and operating margin. Investors should tread carefully, as the stock’s market price appears disconnected from its intrinsic value.